Acadian Asset Management LLC Aligos Therapeutics, Inc. Transaction History

Acadian Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$0.35 - $1.07 $60,021 - $183,494	171,490 Added 26.06%	829,485 $289,000
Q1 2024 May 10, 2024	BUY	$0.64 - $1.13 $63,121 - $111,449	98,628 Added 17.63%	657,995 $644,000
Q4 2023 Feb 13, 2024	SELL	$0.56 - $0.8 $2,994 - $4,278	-5,348 Reduced 0.95%	559,367 $370,000
Q1 2023 May 11, 2023	BUY	$0.87 - $2.11 $200,109 - $485,323	230,011 Added 68.72%	564,715 $492,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $21,592 - $560,175	20,370 Added 6.48%	334,704 $366,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $21,592 - $560,175	20,370 Added 6.48%	334,704 $366,000
Q2 2022 Aug 09, 2022	BUY	$1.04 - $2.14 $144,157 - $296,631	138,613 Added 78.88%	314,334 $380,000
Q1 2022 May 12, 2022	BUY	$2.08 - $12.2 $365,499 - $2.14 Million	175,721 New	175,721 $377,000

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.